EP Patent

EP3626231A1 — Physiologically balanced injectable formulations of fosnetupitant

Assigned to Helsinn Healthcare SA · Expires 2020-03-25 · 6y expired

What this patent protects

Injectable dosages and formulations of fosnetupitant and pharmaceutically acceptable salts thereof are provided that are efficacious, chemically stable and physiologically balanced for safety and efficacy.

USPTO Abstract

Injectable dosages and formulations of fosnetupitant and pharmaceutically acceptable salts thereof are provided that are efficacious, chemically stable and physiologically balanced for safety and efficacy.

Drugs covered by this patent

fosnetupitant-chloride-hydrochloride (FOSNETUPITANT CHLORIDE HYDROCHLORIDE)

Patent Metadata

Patent number: EP3626231A1
Jurisdiction: EP
Classification: —
Expires: 2020-03-25
Drug substance claim: No
Drug product claim: No
Assignee: Helsinn Healthcare SA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.